Novartis Expands Radioligand Therapy Production with Two New US Facilities

Expansion Plans:
Novartis is constructing two new radioligand therapy (RLT) manufacturing facilities in the US, one in Indianapolis and another in Carlsbad, California, to enhance its RLT production and supply chain capabilities.

Production Capacity:
The new facilities aim to increase the production of RLTs, including Pluvicto, to meet growing demand and ensure consistent supply to patients.

Investment in RLT:
Novartis is investing heavily in RLTs, with a focus on expanding their use in various cancer types beyond prostate and neuroendocrine tumors.

Environmental Commitments:
Novartis is also committed to environmental sustainability, aiming to become carbon neutral in its operations by 2025 and across its value chain by 2030, while reducing water consumption and eliminating PVC in packaging.

Pipeline Development:
Novartis has a robust pipeline of RLTs in development, with multiple clinical trials underway or planned to explore their application in different cancer settings.